Literature DB >> 28821197

Regional Variability in Percentage of Breast Cancers Reported as Positive for HER2 in California: Implications of Patient Demographics on Laboratory Benchmarks.

Chieh-Yu Lin1, Eugene E Carneal1, Daphne Y Lichtensztajn2, Scarlett L Gomez2,3, Christina A Clarke2,3, Kristin C Jensen1,4, Allison W Kurian5, Kimberly H Allison1.   

Abstract

OBJECTIVES: The expected regional variability in percent human epidermal growth factor receptor 2 (HER2)-positive breast cancers is not currently clear.
METHODS: Data from the 2006 to 2011 California Cancer Registry were examined by county and health service area. The influence of demographic and pathologic features was used in a multivariable logistic regression model to compare expected with observed HER2-positive percentages by region.
RESULTS: There was significant geographic variation by California counties (11.6%-26%). The reported HER2-positive percentage was higher when the population had higher stage, tumor size, grade, percent estrogen receptor negative, younger age, or lower socioeconomic status. Ethnic distribution of the population also influenced HER2-positive percentages. Using a multivariable logistic regression model, most regions had expected values based on their population characteristics; however, "outlier" regions were identified.
CONCLUSIONS: These results deepen our understanding of population characteristics' influence on the distribution of HER2-positive breast cancers. Taking these factors into account can be useful when setting laboratory benchmarks and assessing test quality. © American Society for Clinical Pathology, 2017. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  Benchmark; Breast cancer; HER2; Positivity rate; Quality; Variability

Mesh:

Substances:

Year:  2017        PMID: 28821197      PMCID: PMC5848426          DOI: 10.1093/ajcp/aqx063

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   5.400


  39 in total

1.  Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.

Authors:  Oliver C Stoss; Andreas Scheel; Iris Nagelmeier; Hans-Ulrich Schildhaus; Thomas Henkel; Giuseppe Viale; Bharat Jasani; Michael Untch; Josef Rüschoff
Journal:  Mod Pathol       Date:  2015-09-25       Impact factor: 7.842

2.  The New Equivocal: Changes to HER2 FISH Results When Applying the 2013 ASCO/CAP Guidelines.

Authors:  Thomas H Long; Helen Lawce; Connie Durum; Stephen R Moore; Susan B Olson; Ken Gatter; Megan L Troxell
Journal:  Am J Clin Pathol       Date:  2015-08       Impact factor: 2.493

3.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

4.  Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.

Authors:  Kathleen A Cronin; Linda C Harlan; Kevin W Dodd; Jeffrey S Abrams; Rachel Ballard-Barbash
Journal:  Cancer Invest       Date:  2010-11       Impact factor: 2.176

5.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

Authors:  B A Gusterson; R D Gelber; A Goldhirsch; K N Price; J Säve-Söderborgh; R Anbazhagan; J Styles; C M Rudenstam; R Golouh; R Reed
Journal:  J Clin Oncol       Date:  1992-07       Impact factor: 44.544

6.  Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

Authors:  Carol A Parise; Katrina R Bauer; Monica M Brown; Vincent Caggiano
Journal:  Breast J       Date:  2009-09-17       Impact factor: 2.431

7.  HER2-positivity rates in breast cancer: no variation over time when clinicopathological features and testing are stable.

Authors:  F Beltjens; A Bertaut; S Pigeonnat; C Loustalot; I Desmoulins; C Charon-Barra; B Coudert; P Fumoleau; P Arveux; L Arnould
Journal:  Eur J Cancer Care (Engl)       Date:  2015-10-27       Impact factor: 2.520

8.  [Impact of 2013 American Society of Clinical Oncology/College of American Pathologist guidelines on borderline immunostaining results for HER2: a retrospective study on HER2 FISH results in 1 780 cases of invasive breast cancers].

Authors:  Y Xu; Q M Bai; F Yang; X L Zhu; Y M Lu; J Zhang; W T Yang; X Y Zhou
Journal:  Zhonghua Bing Li Xue Za Zhi       Date:  2016-08-08

Review 9.  Emerging technologies for assessing HER2 amplification.

Authors:  Frédérique Penault-Llorca; Michael Bilous; Mitch Dowsett; Wedad Hanna; Robert Yoshiyuki Osamura; Josef Rüschoff; Marc van de Vijver
Journal:  Am J Clin Pathol       Date:  2009-10       Impact factor: 2.493

10.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

Authors:  Antonio C Wolff; M Elizabeth H Hammond; David G Hicks; Mitch Dowsett; Lisa M McShane; Kimberly H Allison; Donald C Allred; John M S Bartlett; Michael Bilous; Patrick Fitzgibbons; Wedad Hanna; Robert B Jenkins; Pamela B Mangu; Soonmyung Paik; Edith A Perez; Michael F Press; Patricia A Spears; Gail H Vance; Giuseppe Viale; Daniel F Hayes
Journal:  Arch Pathol Lab Med       Date:  2013-10-07       Impact factor: 5.534

View more
  2 in total

1.  Breast cancer biomarkers in clinical testing: analysis of a UK national external quality assessment scheme for immunocytochemistry and in situ hybridisation database containing results from 199 300 patients.

Authors:  Andrew Dodson; Suzanne Parry; Merdol Ibrahim; John Ms Bartlett; Sarah Pinder; Mitch Dowsett; Keith Miller
Journal:  J Pathol Clin Res       Date:  2018-09-21

2.  The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review.

Authors:  Miriam Van den Nest; Anna Glechner; Maria Gold; Gerald Gartlehner
Journal:  Syst Rev       Date:  2019-12-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.